Glenmark Life Sciences Limited EBIT

The latest EBIT for GLS.NS is $8B as of June 2026. That compares with $6.7B in the prior-year period — up 18.7% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Glenmark Life Sciences Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, GLS.NS's EBIT moved from $6.7B to $8B — a 18.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Glenmark Life Sciences Limited's operating scale or balance-sheet position.

Against its sector companies, GLS.NS currently prints $8B for EBIT, while the sector average sits near $2.6T. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at Glenmark Life Sciences Limited's growth, margins, and balance sheet.

A EBIT figure of $8B for GLS.NS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting GLS.NS's EBIT ($8B), review year-over-year change from $6.7B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.